Depression and anxiety are among the most underrecognized burdens of chronic obstructive pulmonary disease, and a new study suggests that the usual yardstick of COPD severity, forced expiratory volume in one second, may miss much of that psychological weight. In a cross-sectional study of 56 clinically stable Japanese outpatients with COPD, depressive symptoms were present in 46.5 percent of patients and elevated state anxiety in 41.1 percent. What distinguished those with symptoms was not how obstructed their airways were on spirometry, but how well their lungs transferred oxygen at the alveolar-capillary membrane and how much pressure their pulmonary circulation was carrying, as estimated noninvasively by echocardiography.
The study, conducted at the outpatient clinic of Fukuoka National Hospital between June 2014 and March 2015, enrolled patients diagnosed according to Global Initiative for Chronic Obstructive Lung Disease criteria, with a post-bronchodilator FEV1/FVC ratio below 0.70 and no acute exacerbation, systemic corticosteroids, or antibiotics for at least four weeks before assessment. Participants had a mean age of 73.3 years and 87.5 percent were men, spanning GOLD stages I through IV. Each completed the Self-Rating Depression Scale and the State-Trait Anxiety Inventory, and underwent spirometry, single-breath measurement of diffusing capacity per unit of ventilated alveolar volume expressed as percent predicted, echocardiographic assessment of the tricuspid regurgitation pressure gradient, and blood and body-composition measurements including BMI, fat-free mass index, C-reactive protein, and NT-proBNP.
The symptom prevalence figures are striking in their own right. Using Japanese standard cut-offs, 46.5 percent of patients scored in the depressive range on the SDS, including 16.1 percent with moderate and 5.4 percent with severe symptoms. On the state subscale of the STAI, 41.1 percent showed elevated anxiety, with 12.5 percent in the severe category; on the trait subscale, 28.6 percent had elevated anxiety, 14.3 percent of them severe. These figures align with meta-analytic estimates suggesting that depression affects roughly one-third of people with COPD and that anxiety prevalence generally falls between 25 and 40 percent, rates comparable to or exceeding those seen in other chronic diseases such as heart failure and diabetes.
The physiological correlations told a clearer story than airflow measures did. SDS scores were negatively correlated with BMI (r = −0.376, p = 0.005), fat-free mass index (r = −0.310, p = 0.024), and percent predicted DLCO/VA (r = −0.396, p = 0.003), and positively correlated with the tricuspid regurgitation pressure gradient (r = 0.441, p = 0.001). State anxiety scores were positively correlated with TRPG (r = 0.407, p = 0.002), while trait anxiety correlated negatively with BMI and HbA1c. Notably, percent predicted FEV1 showed no significant correlation with any of the psychological scores, all p values above 0.05, reinforcing the authors’ argument that airflow limitation alone does not capture the heterogeneity of psychological symptom burden in COPD.
Multivariable linear regression, adjusted for age, sex, and BMI, sharpened these associations. In a model including percent predicted DLCO/VA, lower diffusing capacity per unit alveolar volume was independently associated with a higher depression score (p = 0.029). In a separate model including TRPG, higher pulmonary hemodynamic burden was independently associated with both higher depression scores (p = 0.001) and higher state anxiety scores (p = 0.002). DLCO/VA reflects integrated abnormalities of ventilation, pulmonary perfusion, and alveolar-capillary diffusion, and has previously emerged as an independent predictor of exacerbations, hospitalization, mortality, and pulmonary hypertension. TRPG, calculated from the maximal tricuspid regurgitation velocity using the simplified Bernoulli equation, serves as a noninvasive surrogate of pulmonary hemodynamic load.
To test whether these regression findings were statistical flukes of a small sample, the researchers ran bootstrap resampling with 1,000 iterations. The TRPG-depression association held up robustly: the regression coefficient was positive in every resample, with a percentile bootstrap 95 percent confidence interval that did not cross zero. For state anxiety, TRPG showed a positive coefficient in 99.6 percent of bootstrap samples. The inverse DLCO/VA association with depression was directionally consistent but less stable, with a bootstrap confidence interval lying close to zero, a nuance the authors flag repeatedly and one that distinguishes the two physiological signals in terms of evidential strength.
Why might gas-exchange impairment and pulmonary vascular load track psychological distress when airflow obstruction does not? The authors propose several interconnected, and explicitly speculative, pathways: diffusion impairment may amplify exertional breathlessness and fear of breathlessness, promoting activity avoidance and a self-reinforcing cognitive-behavioral cycle; elevated pulmonary hemodynamic burden may contribute to exercise intolerance and declining quality of life, patterns documented in pulmonary hypertension cohorts; and low BMI and reduced fat-free mass, which correlated modestly with depressive symptoms in univariable analyses, may connect to depression through systemic inflammation and neuroimmunological mechanisms. Because the study did not measure dyspnea scales or symptom-burden questionnaires, no formal mediation analysis was possible, and the authors caution that these interpretations remain hypothesis-generating.
The limitations deserve as much attention as the findings. This was a single-center study with a small sample, which limits statistical power and the stability of multivariable models. The cross-sectional design precludes any causal inference; psychological distress could just as plausibly worsen physical activity, symptom perception, and clinical status as the reverse. TRPG derived from Doppler echocardiography is a surrogate marker, less accurate than right heart catheterization, and other right-heart parameters such as mean pulmonary artery pressure, the TAPSE/sPAP ratio, and pulmonary vascular resistance were not systematically available. Self-report instruments like the SDS may partly capture somatic distress and fatigue rather than depressive symptomatology per se, and residual confounding by hypoxemia, exacerbation history, medications, smoking status, and comorbidities cannot be excluded.
Generalizability is a further constraint. The cohort consisted predominantly of older Japanese men with a relatively low mean BMI of 22.0 kg/m², and body habitus, obesity prevalence, and phenotypic distribution differ substantially from Western COPD populations. BMI and fat-free mass index also declined significantly across GOLD stages in this cohort, hinting at the nutritional and sarcopenic dimension of advanced disease. Whether the same physiological-psychological relationships hold in more diverse populations, in women, or in patients with different smoking and exposure histories remains an open question that larger, ideally longitudinal, studies will need to answer.
Even with those caveats, the clinical message is coherent with the direction of contemporary COPD thinking. GOLD frameworks already emphasize multidimensional assessment that extends beyond spirometric severity, and prior work has linked impaired diffusing capacity to exercise intolerance, pulmonary vascular involvement, and adverse outcomes, while a recent meta-registry analysis of COPD-associated pulmonary hypertension identified pulmonary vascular resistance, not FEV1, as a major predictor of outcome. The authors argue that incorporating physiological markers such as DLCO/VA and TRPG, alongside validated psychological screening tools, could support an integrated biopsychosocial approach to routine COPD care, helping clinicians identify patients whose psychological burden would otherwise remain invisible behind adequate airflow numbers. Given that depression and anxiety in COPD are associated with 1.4 to 2.1-fold increased risks of acute exacerbations and with higher hospitalization and mortality rates, yet remain frequently underrecognized and undertreated, any tool that surfaces this comorbidity earlier carries real clinical stakes. Confirmation in larger and more diverse cohorts is the necessary next step.
Subject of Research: Associations of depressive and anxiety symptoms with diffusion impairment and pulmonary hemodynamic burden in COPD
Article Title: Depressive and anxiety symptoms in COPD: associations with diffusion impairment and echocardiographic pulmonary hemodynamic burden
Article References: Hiramoto, T., Izuno, S., Toda, K., Moriwaki, A., & Yoshida, M. (2026). Depressive and anxiety symptoms in COPD: associations with diffusion impairment and echocardiographic pulmonary hemodynamic burden. BioPsychoSocial Medicine, 20(1), Article 17. https://doi.org/10.1186/s13030-026-00364-0
Image Credits: AI Generated
DOI: 10.1186/s13030-026-00364-0
Keywords: COPD, depression, anxiety, DLCO, tricuspid regurgitation pressure gradient, pulmonary hemodynamics, echocardiography, spirometry, cross-sectional study, biopsychosocial assessment, BMI, fat-free mass index
News Source: Glenn Wilkins. (October 29, 2026). Beyond Airflow: Lung Diffusion and Heart Strain Track Depression and Anxiety in COPD. Scienmag.
